[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565828":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":43,"locations":49,"responsibleParty":67,"collaborators":30,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":30,"enrollmentInfo":79,"targetDuration":30,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":30,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Institut Mutualiste Montsouris","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Q-MODE","ACTIVE_COMPARATOR","Radiofrequency ablation with High Power - Short Duration (HPSD) up to 50W.",[13],"Procedure: Q-MODE : radiofrequency ablation up to 50W",{"label":15,"type":10,"description":16,"interventionNames":17},"Q-MODE+","Radiofrequency ablation with High Power - Short Duration (HPSD) up to 90W.",[18],"Procedure: Q-MODE+ : radiofrequency up to 90W",{"label":20,"type":10,"description":21,"interventionNames":22},"Hybride Q-MODE\u002FQ-MODE+","A combination of the two ablation methods.",[23],"Procedure: Hybride Q-MODE\u002FQ-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part",[25,31,35],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"PROCEDURE","Q-MODE : radiofrequency ablation up to 50W","The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.\n\nFor patient randomized in this arm, the device is set to Q-MODE option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 50W.",[9],null,{"type":26,"name":32,"description":33,"armGroupLabels":34,"otherNames":30},"Q-MODE+ : radiofrequency up to 90W","The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.\n\nFor patient randomized in this arm, the device is set to Q-MODE+ option: the intensity of radiofrequency to isolate the pulmonary vein is limited to 90W.",[15],{"type":26,"name":36,"description":37,"armGroupLabels":38,"otherNames":30},"Hybride Q-MODE\u002FQ-MODE+: radiofrequency ablation up to 50W in the anterior part, and 90W in the posterior part","The same device (QDOT Micro™) is used in all 3 arms of this trial. The 3 strategies of radiofrequency delivery within the 3 arms are already used in the standard of care.\n\nFor patient randomized in this arm, the device is set to \"Q-MODE\u002FQ-MODE+\" option: the intensity of radiofrequency delivered to isolate the pulmonary vein is limited to 50W in the anterior part and to 90W in the posterior part.",[20],[40],{"name":41,"affiliation":5,"role":42},"Frédéric SEBAG","PRINCIPAL_INVESTIGATOR",[44],{"name":45,"role":46,"phone":47,"phoneExt":30,"email":48},"Naly ANDRIAMBAO","CONTACT","+33156616439","naly.andriambao@imm.fr",[50],{"facility":5,"status":51,"city":52,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"RECRUITING","Paris","75014","France","FR",{"type":57,"coordinates":58},"Point",[59,60],2.3488,48.85341,{"lat":60,"lon":59},[63],{"name":64,"role":46,"phone":65,"phoneExt":30,"email":66},"Frederic SEBAG","+33156616263","frederic.sebag@imm.fr",{"type":68,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100565828","comparison-of-3-rf-delivery-modes-of-the-qdot-catheter-for-paroxymal-atrial-fibrillation-af-ablation-100565828",false,"NCT06647251","Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal Atrial Fibrillation (AF) Ablation","Comparison of 3 RF Delivery Modes of the QDOT Catheter for Paroxymal AF Ablation: a Prospective Study","QDOT","Inclusion Criteria:\n\n* Patient aged 18 or over\n* First atrial fibrillation ablation\n* Paroxysmal atrial fibillation defined as atrial fibrillation lasting less than 48 hours\n* Early atrial fibrillation defined as atrial fibrillation lastiing between 7 days and 3 months\n* At least one episode of atrial fibrillation in the year preceding study entry\n* Patient affiliated to a health insurance\n\nExclusion Criteria:\n\n* History of atrial fibrillation ablation (surgery or catheter)\n* Documented left atrial thrombus\n* Left atrial (LA) diameter \\> 60mm \u002F LA area \\> 35cm2 \u002F Left atrial volulme index (LAVI) \\> 45ml\u002Fm2\n* N\u002FSTEMI replacement or angioplasty or valve within 3 months prior to registration\n* Any contraindication mentioned in the instructions for use of the QDOT MICRO™ bidirectional navigation catheter\n* Patient unable to understand study information\n* Patient deprived of liberty by judicial or administrative decision","ALL","18 Years",{"count":80,"type":81},90,"ESTIMATED","INTERVENTIONAL",[84],"NA","Pulmonary vein isolation is the main treatment of paroxysmal and persistent atrial fibrillation.\n\nThe aim of our study is to prospectively compare the efficacy and safety of the 3 options of radiofrequency delivery with QDOT Micro™, with systematic use of catheter stabilization tools and tighter lesions",[87],"Atrial Fibrillation","2024-10-16",{"date":90,"type":91},"2024-10-17","ACTUAL",{"date":93,"type":81},"2024-10",{"date":95,"type":81},"2028-10",{"name":5,"class":6},1]